{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:00:55Z","timestamp":1790200855921,"version":"4.1.0"},"publisher-location":"Cham","reference-count":270,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030326555","type":"print"},{"value":"9783030326562","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-32656-2_16","type":"book-chapter","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T06:05:12Z","timestamp":1578031512000},"page":"351-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Wnt\/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance"],"prefix":"10.1007","author":[{"given":"Yunshin","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaozhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Prieto-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,4]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/00000658-194206000-00030","volume":"115","author":"C Huggins","year":"1942","unstructured":"C. Huggins, Effect of orchiectomy and irradiation on cancer of the prostate. Ann. Surg. 115, 1192\u20131200 (1942)","journal-title":"Ann. Surg."},{"key":"16_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.juro.2013.05.005","volume":"190","author":"MS Cookson","year":"2013","unstructured":"M.S. Cookson et al., Castration-resistant prostate cancer: AUA Guideline. J. Urol. 190, 429\u2013438 (2013)","journal-title":"J. Urol."},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1056\/NEJMp048178","volume":"351","author":"JD Debes","year":"2004","unstructured":"J.D. Debes, D.J. Tindall, Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351, 1488\u20131490 (2004)","journal-title":"N. Engl. J. Med."},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jcb.20794","volume":"99","author":"SM Dehm","year":"2006","unstructured":"S.M. Dehm, D.J. Tindall, Molecular regulation of androgen action in prostate cancer. J. Cell. Biochem. 99, 333\u2013344 (2006)","journal-title":"J. Cell. Biochem."},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1210\/me.2007-0223","volume":"21","author":"SM Dehm","year":"2007","unstructured":"S.M. Dehm, D.J. Tindall, Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol. 21, 2855\u20132863 (2007)","journal-title":"Mol. Endocrinol."},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"T. Karantanos, P.G. Corn, T.C. Thompson, Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32, 5501\u20135511 (2013)","journal-title":"Oncogene"},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"J.L. Bishop et al., The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54\u201371 (2017)","journal-title":"Cancer Discov."},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"B.J. Feldman, D. Feldman, The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34\u201345 (2001)","journal-title":"Nat. Rev. Cancer"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"P.A. Watson, V.K. Arora, C.L. Sawyers, Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015)","journal-title":"Nat. Rev. Cancer"},{"key":"16_CR10","first-page":"3550","volume":"61","author":"MJ Linja","year":"2001","unstructured":"M.J. Linja et al., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550\u20133555 (2001)","journal-title":"Cancer Res."},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"C.D. Chen et al., Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33\u201339 (2004)","journal-title":"Nat. Med."},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","volume":"10","author":"JL Mohler","year":"2004","unstructured":"J.L. Mohler et al., The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10, 440\u2013448 (2004)","journal-title":"Clin. Cancer Res."},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","volume":"68","author":"JA Locke","year":"2008","unstructured":"J.A. Locke et al., Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407\u20136415 (2008)","journal-title":"Cancer Res."},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"R.B. Montgomery et al., Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447\u20134454 (2008)","journal-title":"Cancer Res."},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/JOE-11-0315","volume":"212","author":"T Saloniemi","year":"2012","unstructured":"T. Saloniemi, H. Jokela, L. Strauss, P. Pakarinen, M. Poutanen, The diversity of sex steroid action: novel functions of hydroxysteroid (17beta) dehydrogenases as revealed by genetically modified mouse models. J. Endocrinol. 212, 27\u201340 (2012)","journal-title":"J. Endocrinol."},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1021\/jm00013a022","volume":"38","author":"GA Potter","year":"1995","unstructured":"G.A. Potter, S.E. Barrie, M. Jarman, M.G. Rowlands, Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463\u20132471 (1995)","journal-title":"J. Med. Chem."},{"key":"16_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/76287","volume":"6","author":"XY Zhao","year":"2000","unstructured":"X.Y. Zhao et al., Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703\u2013706 (2000)","journal-title":"Nat. Med."},{"key":"16_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"R. Hu et al., Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16\u201322 (2009)","journal-title":"Cancer Res."},{"key":"16_CR19","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Z. Guo et al., A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305\u20132313 (2009)","journal-title":"Cancer Res."},{"key":"16_CR20","doi-asserted-by":"publisher","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","volume":"287","author":"SC Chan","year":"2012","unstructured":"S.C. Chan, Y. Li, S.M. Dehm, Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J. Biol. Chem. 287, 19736\u201319749 (2012)","journal-title":"J. Biol. Chem."},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"S.M. Dehm, L.J. Schmidt, H.V. Heemers, R.L. Vessella, D.J. Tindall, Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469\u20135477 (2008)","journal-title":"Cancer Res."},{"key":"16_CR22","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1530\/ERC-11-0141","volume":"18","author":"SM Dehm","year":"2011","unstructured":"S.M. Dehm, D.J. Tindall, Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer 18, R183\u2013R196 (2011)","journal-title":"Endocr. Relat. Cancer"},{"key":"16_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13668","volume":"7","author":"C Henzler","year":"2016","unstructured":"C. Henzler et al., Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat. Commun. 7, 13668 (2016)","journal-title":"Nat. Commun."},{"key":"16_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","volume":"73","author":"Y Li","year":"2013","unstructured":"Y. Li et al., Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73, 483\u2013489 (2013)","journal-title":"Cancer Res."},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1210\/en.2017-00109","volume":"158","author":"Y Ho","year":"2017","unstructured":"Y. Ho, S.M. Dehm, Androgen receptor rearrangement and splicing variants in resistance to endocrine therapies in prostate cancer. Endocrinology 158, 1533\u20131542 (2017)","journal-title":"Endocrinology"},{"key":"16_CR26","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1158\/0008-5472.CAN-07-1267","volume":"67","author":"SM Dehm","year":"2007","unstructured":"S.M. Dehm, K.M. Regan, L.J. Schmidt, D.J. Tindall, Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res. 67, 10067\u201310077 (2007)","journal-title":"Cancer Res."},{"key":"16_CR27","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","volume":"332","author":"ME Taplin","year":"1995","unstructured":"M.E. Taplin et al., Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393\u20131398 (1995)","journal-title":"N. Engl. J. Med."},{"key":"16_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"C.S. Grasso et al., The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239\u2013243 (2012)","journal-title":"Nature"},{"key":"16_CR29","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"E.S. Antonarakis et al., AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038 (2014)","journal-title":"N. Engl. J. Med."},{"key":"16_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","volume":"138","author":"Q Wang","year":"2009","unstructured":"Q. Wang et al., Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245\u2013256 (2009)","journal-title":"Cell"},{"key":"16_CR31","first-page":"172","volume":"6","author":"ZM Connelly","year":"2018","unstructured":"Z.M. Connelly et al., Foxa2 activates the transcription of androgen receptor target genes in castrate resistant prostatic tumors. Am. J. Clin. Exp. Urol. 6, 172\u2013181 (2018)","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"16_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"C. Tran et al., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787\u2013790 (2009)","journal-title":"Science"},{"key":"16_CR33","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"J.S. de Bono et al., Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011)","journal-title":"N. Engl. J. Med."},{"key":"16_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"S. Wang et al., Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209\u2013221 (2003)","journal-title":"Cancer Cell"},{"key":"16_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/pros.20877","volume":"69","author":"X Yu","year":"2009","unstructured":"X. Yu et al., Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 69, 249\u2013262 (2009)","journal-title":"Prostate"},{"key":"16_CR36","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1158\/0008-5472.CAN-06-3028","volume":"67","author":"KJ Bruxvoort","year":"2007","unstructured":"K.J. Bruxvoort et al., Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res. 67, 2490\u20132496 (2007)","journal-title":"Cancer Res."},{"key":"16_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"A.H. Davies, H. Beltran, A. Zoubeidi, Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15, 271\u2013286 (2018)","journal-title":"Nat. Rev. Urol."},{"key":"16_CR38","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"V.K. Arora et al., Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309\u20131322 (2013)","journal-title":"Cell"},{"key":"16_CR39","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"H. Beltran et al., Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20, 2846\u20132850 (2014)","journal-title":"Clin. Cancer Res."},{"key":"16_CR40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2003.11.032","volume":"45","author":"D Hirano","year":"2004","unstructured":"D. Hirano, Y. Okada, S. Minei, Y. Takimoto, N. Nemoto, Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 45, 586\u201392; discussion 592 (2004)","journal-title":"Eur. Urol."},{"key":"16_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrurol.2014.21","volume":"11","author":"R Nadal","year":"2014","unstructured":"R. Nadal, M. Schweizer, O.N. Kryvenko, J.I. Epstein, M.A. Eisenberger, Small cell carcinoma of the prostate. Nat. Rev. Urol. 11, 213\u2013219 (2014)","journal-title":"Nat. Rev. Urol."},{"key":"16_CR42","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"R. Aggarwal et al., Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492\u20132503 (2018)","journal-title":"J. Clin. Oncol."},{"key":"16_CR43","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","volume":"38","author":"JI Epstein","year":"2014","unstructured":"J.I. Epstein et al., Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756\u2013767 (2014)","journal-title":"Am. J. Surg. Pathol."},{"key":"16_CR44","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1158\/0008-5472.CAN-08-2229","volume":"68","author":"X Deng","year":"2008","unstructured":"X. Deng et al., Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res. 68, 9663\u20139670 (2008)","journal-title":"Cancer Res."},{"key":"16_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S","volume":"39","author":"PA Abrahamsson","year":"1999","unstructured":"P.A. Abrahamsson, Neuroendocrine differentiation in prostatic carcinoma. Prostate 39, 135\u2013148 (1999)","journal-title":"Prostate"},{"key":"16_CR46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R","volume":"42","author":"G Ahlgren","year":"2000","unstructured":"G. Ahlgren et al., Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42, 274\u2013279 (2000)","journal-title":"Prostate"},{"key":"16_CR47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0090-4295(97)00684-5","volume":"51","author":"T Jiborn","year":"1998","unstructured":"T. Jiborn, A. Bjartell, P.A. Abrahamsson, Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51, 585\u2013589 (1998)","journal-title":"Urology"},{"key":"16_CR48","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fonc.2014.00060","volume":"4","author":"S Terry","year":"2014","unstructured":"S. Terry, H. Beltran, The many faces of neuroendocrine differentiation in prostate cancer progression. Front. Oncol. 4, 60 (2014)","journal-title":"Front. Oncol."},{"key":"16_CR49","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1200\/JCO.2011.41.5166","volume":"30","author":"H Beltran","year":"2012","unstructured":"H. Beltran et al., Challenges in recognizing treatment-related neuroendocrine prostate cancer. J. Clin. Oncol. 30, e386\u2013e389 (2012)","journal-title":"J. Clin. Oncol."},{"key":"16_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/neo.121550","volume":"15","author":"JM Mosquera","year":"2013","unstructured":"J.M. Mosquera et al., Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1\u201310 (2013)","journal-title":"Neoplasia"},{"key":"16_CR51","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/pros.20434","volume":"66","author":"J Huang","year":"2006","unstructured":"J. Huang et al., Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 66, 1399\u20131406 (2006)","journal-title":"Prostate"},{"key":"16_CR52","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1078-0432.CCR-11-1867","volume":"18","author":"V Tzelepi","year":"2012","unstructured":"V. Tzelepi et al., Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin. Cancer Res. 18, 666\u2013677 (2012)","journal-title":"Clin. Cancer Res."},{"key":"16_CR53","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/00000478-200606000-00005","volume":"30","author":"JL Yao","year":"2006","unstructured":"J.L. Yao et al., Small cell carcinoma of the prostate: an immunohistochemical study. Am. J. Surg. Pathol. 30, 705\u2013712 (2006)","journal-title":"Am. J. Surg. Pathol."},{"key":"16_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/pcan.2014.29","volume":"17","author":"X Yu","year":"2014","unstructured":"X. Yu et al., SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis. 17, 301\u2013309 (2014)","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"16_CR55","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1677\/ERC-07-0061","volume":"14","author":"TC Yuan","year":"2007","unstructured":"T.C. Yuan, S. Veeramani, M.F. Lin, Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr. Relat. Cancer 14, 531\u2013547 (2007)","journal-title":"Endocr. Relat. Cancer"},{"key":"16_CR56","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1210\/me.2003-0031","volume":"17","author":"ME Wright","year":"2003","unstructured":"M.E. Wright, M.J. Tsai, R. Aebersold, Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol. Endocrinol. 17, 1726\u20131737 (2003)","journal-title":"Mol. Endocrinol."},{"key":"16_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1078-1439(97)00039-2","volume":"3","author":"R Shen","year":"1997","unstructured":"R. Shen et al., Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol. Oncol. 3, 67\u201375 (1997)","journal-title":"Urol. Oncol."},{"key":"16_CR58","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1593\/neo.07562","volume":"9","author":"WJ Huss","year":"2007","unstructured":"W.J. Huss et al., Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 9, 938\u2013950 (2007)","journal-title":"Neoplasia"},{"key":"16_CR59","first-page":"4687","volume":"57","author":"JR Gingrich","year":"1997","unstructured":"J.R. Gingrich et al., Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57, 4687\u20134691 (1997)","journal-title":"Cancer Res."},{"key":"16_CR60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/pros.20148","volume":"62","author":"MA Johnson","year":"2005","unstructured":"M.A. Johnson et al., Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Prostate 62, 322\u2013338 (2005)","journal-title":"Prostate"},{"key":"16_CR61","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","volume":"74","author":"D Lin","year":"2014","unstructured":"D. Lin et al., High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272\u20131283 (2014)","journal-title":"Cancer Res."},{"key":"16_CR62","first-page":"859","volume":"149","author":"MA Noordzij","year":"1996","unstructured":"M.A. Noordzij et al., Neuroendocrine differentiation in human prostatic tumor models. Am. J. Pathol. 149, 859\u2013871 (1996)","journal-title":"Am. J. Pathol."},{"key":"16_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0002-9440(10)65300-X","volume":"154","author":"J Jongsma","year":"1999","unstructured":"J. Jongsma et al., Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am. J. Pathol. 154, 543\u2013551 (1999)","journal-title":"Am. J. Pathol."},{"key":"16_CR64","doi-asserted-by":"publisher","first-page":"13812","DOI":"10.1074\/jbc.275.18.13812","volume":"275","author":"ME Cox","year":"2000","unstructured":"M.E. Cox, P.D. Deeble, E.A. Bissonette, S.J. Parsons, Activated 3\u2032,5\u2032-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J. Biol. Chem. 275, 13812\u201313818 (2000)","journal-title":"J. Biol. Chem."},{"key":"16_CR65","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.1128\/MCB.21.24.8471-8482.2001","volume":"21","author":"PD Deeble","year":"2001","unstructured":"P.D. Deeble, D.J. Murphy, S.J. Parsons, M.E. Cox, Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol. Cell. Biol. 21, 8471\u20138482 (2001)","journal-title":"Mol. Cell. Biol."},{"key":"16_CR66","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1158\/0008-5472.CAN-05-0162","volume":"65","author":"X Yang","year":"2005","unstructured":"X. Yang et al., A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res. 65, 5263\u20135271 (2005)","journal-title":"Cancer Res."},{"key":"16_CR67","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"E. Dardenne et al., N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563\u2013577 (2016)","journal-title":"Cancer Cell"},{"key":"16_CR68","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","volume":"29","author":"JK Lee","year":"2016","unstructured":"J.K. Lee et al., N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell 29, 536\u2013547 (2016)","journal-title":"Cancer Cell"},{"key":"16_CR69","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"S.Y. Ku et al., Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017)","journal-title":"Science"},{"key":"16_CR70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"P. Mu et al., SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84\u201388 (2017)","journal-title":"Science"},{"key":"16_CR71","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/1541-7786.MCR-11-0296","volume":"10","author":"G Danza","year":"2012","unstructured":"G. Danza et al., Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol. Cancer Res. 10, 230\u2013238 (2012)","journal-title":"Mol. Cancer Res."},{"key":"16_CR72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2010.05.024","volume":"18","author":"J Qi","year":"2010","unstructured":"J. Qi et al., Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18, 23\u201338 (2010)","journal-title":"Cancer Cell"},{"key":"16_CR73","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tranon.2017.01.011","volume":"10","author":"SS Yadav","year":"2017","unstructured":"S.S. Yadav et al., Induction of neuroendocrine differentiation in prostate cancer cells by dovitinib (TKI-258) and its therapeutic implications. Transl. Oncol. 10, 357\u2013366 (2017)","journal-title":"Transl. Oncol."},{"key":"16_CR74","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pros.2990190202","volume":"19","author":"H Bonkhoff","year":"1991","unstructured":"H. Bonkhoff, N. Wernert, G. Dhom, K. Remberger, Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 19, 91\u201398 (1991)","journal-title":"Prostate"},{"key":"16_CR75","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.urolonc.2009.09.013","volume":"29","author":"N Dizeyi","year":"2011","unstructured":"N. Dizeyi et al., Serotonin activates MAP kinase and PI3K\/Akt signaling pathways in prostate cancer cell lines. Urol. Oncol. 29, 436\u2013445 (2011)","journal-title":"Urol. Oncol."},{"key":"16_CR76","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/pros.20369","volume":"66","author":"K Uchida","year":"2006","unstructured":"K. Uchida et al., Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 66, 536\u2013545 (2006)","journal-title":"Prostate"},{"key":"16_CR77","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/labinvest.2014.165","volume":"95","author":"K Hashimoto","year":"2015","unstructured":"K. Hashimoto et al., The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells. Lab. Investig. 95, 283\u2013295 (2015)","journal-title":"Lab. Investig."},{"key":"16_CR78","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.humpath.2005.02.019","volume":"36","author":"R Grobholz","year":"2005","unstructured":"R. Grobholz et al., Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum. Pathol. 36, 562\u2013570 (2005)","journal-title":"Hum. Pathol."},{"key":"16_CR79","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1158\/0008-5472.CAN-03-3117","volume":"64","author":"RJ Jin","year":"2004","unstructured":"R.J. Jin et al., NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 64, 5489\u20135495 (2004)","journal-title":"Cancer Res."},{"key":"16_CR80","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1074\/jbc.M116.755082","volume":"292","author":"J Szczyrba","year":"2017","unstructured":"J. Szczyrba et al., Neuroendocrine cells of the prostate derive from the neural crest. J. Biol. Chem. 292, 2021\u20132031 (2017)","journal-title":"J. Biol. Chem."},{"key":"16_CR81","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","volume":"7","author":"M Zou","year":"2017","unstructured":"M. Zou et al., Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 7, 736\u2013749 (2017)","journal-title":"Cancer Discov."},{"key":"16_CR82","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/pros.20910","volume":"69","author":"DE Hansel","year":"2009","unstructured":"D.E. Hansel et al., Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69, 603\u2013609 (2009)","journal-title":"Prostate"},{"key":"16_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/pros.20338","volume":"66","author":"CG Sauer","year":"2006","unstructured":"C.G. Sauer, A. Roemer, R. Grobholz, Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate 66, 227\u2013234 (2006)","journal-title":"Prostate"},{"key":"16_CR84","doi-asserted-by":"publisher","first-page":"9544","DOI":"10.1158\/0008-5472.CAN-10-1638","volume":"70","author":"NC Bastus","year":"2010","unstructured":"N.C. Bastus et al., Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 70, 9544\u20139548 (2010)","journal-title":"Cancer Res."},{"key":"16_CR85","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"H. Beltran et al., Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487\u2013495 (2011)","journal-title":"Cancer Discov."},{"key":"16_CR86","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"M.G. Oser, M.J. Niederst, L.V. Sequist, J.A. Engelman, Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 16, e165\u2013e172 (2015)","journal-title":"Lancet Oncol."},{"key":"16_CR87","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"H. Beltran et al., Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305 (2016)","journal-title":"Nat. Med."},{"key":"16_CR88","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2016.04.028","volume":"71","author":"Y Li","year":"2017","unstructured":"Y. Li et al., SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition. Eur. Urol. 71, 68\u201378 (2017)","journal-title":"Eur. Urol."},{"key":"16_CR89","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1038\/onc.2017.50","volume":"36","author":"J Kim","year":"2017","unstructured":"J. Kim et al., FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene 36, 4072\u20134080 (2017)","journal-title":"Oncogene"},{"key":"16_CR90","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/pros.20299","volume":"66","author":"J Mirosevich","year":"2006","unstructured":"J. Mirosevich et al., Expression and role of Foxa proteins in prostate cancer. Prostate 66, 1013\u20131028 (2006)","journal-title":"Prostate"},{"key":"16_CR91","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/pros.20131","volume":"62","author":"J Mirosevich","year":"2005","unstructured":"J. Mirosevich, N. Gao, R.J. Matusik, Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate 62, 339\u2013352 (2005)","journal-title":"Prostate"},{"key":"16_CR92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13148-015-0074-4","volume":"7","author":"PL Clermont","year":"2015","unstructured":"P.L. Clermont et al., Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics 7, 40 (2015)","journal-title":"Clin. Epigenetics"},{"key":"16_CR93","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/srep01911","volume":"3","author":"T Sato","year":"2013","unstructured":"T. Sato et al., PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci. Rep. 3, 1911 (2013)","journal-title":"Sci. Rep."},{"key":"16_CR94","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.humpath.2010.09.019","volume":"42","author":"JJ Findeis-Hosey","year":"2011","unstructured":"J.J. Findeis-Hosey et al., High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. Hum. Pathol. 42, 867\u2013872 (2011)","journal-title":"Hum. Pathol."},{"key":"16_CR95","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nrc2736","volume":"9","author":"AP Bracken","year":"2009","unstructured":"A.P. Bracken, K. Helin, Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9, 773\u2013784 (2009)","journal-title":"Nat. Rev. Cancer"},{"key":"16_CR96","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1073\/pnas.0409875102","volume":"102","author":"A Kuzmichev","year":"2005","unstructured":"A. Kuzmichev et al., Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U. S. A. 102, 1859\u20131864 (2005)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR97","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1038\/cddis.2011.84","volume":"2","author":"H Richly","year":"2011","unstructured":"H. Richly, L. Aloia, L. Di Croce, Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2, e204 (2011)","journal-title":"Cell Death Dis."},{"key":"16_CR98","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","volume":"14","author":"A Laugesen","year":"2014","unstructured":"A. Laugesen, K. Helin, Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 14, 735\u2013751 (2014)","journal-title":"Cell Stem Cell"},{"key":"16_CR99","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ceb.2015.10.003","volume":"37","author":"E Conway","year":"2015","unstructured":"E. Conway, E. Healy, A.P. Bracken, PRC2 mediated H3K27 methylations in cellular identity and cancer. Curr. Opin. Cell Biol. 37, 42\u201348 (2015)","journal-title":"Curr. Opin. Cell Biol."},{"key":"16_CR100","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/febs.13083","volume":"282","author":"P Vizan","year":"2015","unstructured":"P. Vizan, M. Beringer, C. Ballare, L. Di Croce, Role of PRC2-associated factors in stem cells and disease. FEBS J. 282, 1723\u20131735 (2015)","journal-title":"FEBS J."},{"key":"16_CR101","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1101\/gad.381706","volume":"20","author":"AP Bracken","year":"2006","unstructured":"A.P. Bracken, N. Dietrich, D. Pasini, K.H. Hansen, K. Helin, Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 1123\u20131136 (2006)","journal-title":"Genes Dev."},{"key":"16_CR102","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1101\/gad.1742509","volume":"23","author":"H Chen","year":"2009","unstructured":"H. Chen et al., Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a\/Arf expression and regeneration in diabetes mellitus. Genes Dev. 23, 975\u2013985 (2009)","journal-title":"Genes Dev."},{"key":"16_CR103","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1210\/en.2010-0436","volume":"151","author":"LR Bohrer","year":"2010","unstructured":"L.R. Bohrer, S. Chen, T.C. Hallstrom, H. Huang, Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology 151, 5136\u20135145 (2010)","journal-title":"Endocrinology"},{"key":"16_CR104","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1038\/s41467-018-06177-2","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Y. Zhang et al., Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nat. Commun. 9, 4080 (2018)","journal-title":"Nat. Commun."},{"key":"16_CR105","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/15592294.2016.1146851","volume":"11","author":"B Kleb","year":"2016","unstructured":"B. Kleb et al., Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics 11, 184\u2013193 (2016)","journal-title":"Epigenetics"},{"key":"16_CR106","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.urolonc.2017.12.021","volume":"36","author":"AV Sheahan","year":"2018","unstructured":"A.V. Sheahan, L. Ellis, Epigenetic reprogramming: a key mechanism driving therapeutic resistance. Urol. Oncol. 36, 375\u2013379 (2018)","journal-title":"Urol. Oncol."},{"key":"16_CR107","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","volume":"20","author":"HL Tan","year":"2014","unstructured":"H.L. Tan et al., Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890\u2013903 (2014)","journal-title":"Clin. Cancer Res."},{"key":"16_CR108","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","volume":"63","author":"H Beltran","year":"2013","unstructured":"H. Beltran et al., Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920\u2013926 (2013)","journal-title":"Eur. Urol."},{"key":"16_CR109","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","volume":"44","author":"M Peifer","year":"2012","unstructured":"M. Peifer et al., Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104\u20131110 (2012)","journal-title":"Nat. Genet."},{"key":"16_CR110","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1530\/ERC-11-0368","volume":"19","author":"H Chen","year":"2012","unstructured":"H. Chen et al., Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr. Relat. Cancer 19, 321\u2013331 (2012)","journal-title":"Endocr. Relat. Cancer"},{"key":"16_CR111","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrurol.2011.107","volume":"8","author":"A Aparicio","year":"2011","unstructured":"A. Aparicio, R.B. Den, K.E. Knudsen, Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat. Rev. Urol. 8, 562\u2013568 (2011)","journal-title":"Nat. Rev. Urol."},{"key":"16_CR112","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2353\/ajpath.2008.070602","volume":"172","author":"T Chiaverotti","year":"2008","unstructured":"T. Chiaverotti et al., Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am. J. Pathol. 172, 236\u2013246 (2008)","journal-title":"Am. J. Pathol."},{"key":"16_CR113","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.1158\/0008-5472.CAN-06-0486","volume":"66","author":"Z Zhou","year":"2006","unstructured":"Z. Zhou et al., Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 66, 7889\u20137898 (2006)","journal-title":"Cancer Res."},{"key":"16_CR114","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/bcr2214","volume":"10","author":"AM Pietersen","year":"2008","unstructured":"A.M. Pietersen et al., EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 10, R109 (2008)","journal-title":"Breast Cancer Res."},{"key":"16_CR115","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1038\/sj.onc.1207706","volume":"23","author":"X Tang","year":"2004","unstructured":"X. Tang et al., Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23, 5759\u20135769 (2004)","journal-title":"Oncogene"},{"key":"16_CR116","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","volume":"22","author":"AP Bracken","year":"2003","unstructured":"A.P. Bracken et al., EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323\u20135335 (2003)","journal-title":"EMBO J."},{"key":"16_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071670","volume":"8","author":"BP Coe","year":"2013","unstructured":"B.P. Coe et al., Genomic deregulation of the E2F\/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. PLoS One 8, e71670 (2013)","journal-title":"PLoS One"},{"key":"16_CR118","first-page":"REVIEWS3001","volume":"3","author":"JR Miller","year":"2002","unstructured":"J.R. Miller, The Wnts. Genome Biol. 3, REVIEWS3001 (2002)","journal-title":"Genome Biol."},{"key":"16_CR119","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1242\/jcs.00623","volume":"116","author":"Y Kawano","year":"2003","unstructured":"Y. Kawano, R. Kypta, Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116, 2627\u20132634 (2003)","journal-title":"J. Cell Sci."},{"key":"16_CR120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"J.N. Anastas, R.T. Moon, WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11\u201326 (2013)","journal-title":"Nat. Rev. Cancer"},{"key":"16_CR121","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ceb.2005.08.009","volume":"17","author":"J Lilien","year":"2005","unstructured":"J. Lilien, J. Balsamo, The regulation of cadherin-mediated adhesion by tyrosine phosphorylation\/dephosphorylation of beta-catenin. Curr. Opin. Cell Biol. 17, 459\u2013465 (2005)","journal-title":"Curr. Opin. Cell Biol."},{"key":"16_CR122","doi-asserted-by":"publisher","first-page":"10173","DOI":"10.1074\/jbc.274.15.10173","volume":"274","author":"T Muller","year":"1999","unstructured":"T. Muller, A. Choidas, E. Reichmann, A. Ullrich, Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J. Biol. Chem. 274, 10173\u201310183 (1999)","journal-title":"J. Biol. Chem."},{"key":"16_CR123","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2164-15-74","volume":"15","author":"A Herbst","year":"2014","unstructured":"A. Herbst et al., Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt\/beta-catenin signaling. BMC Genomics 15, 74 (2014)","journal-title":"BMC Genomics"},{"key":"16_CR124","doi-asserted-by":"publisher","first-page":"11336","DOI":"10.1074\/jbc.M111962200","volume":"277","author":"F Yang","year":"2002","unstructured":"F. Yang et al., Linking beta-catenin to androgen-signaling pathway. J. Biol. Chem. 277, 11336\u201311344 (2002)","journal-title":"J. Biol. Chem."},{"key":"16_CR125","doi-asserted-by":"publisher","first-page":"10747","DOI":"10.1073\/pnas.0604206103","volume":"103","author":"MV Hadjihannas","year":"2006","unstructured":"M.V. Hadjihannas et al., Aberrant Wnt\/beta-catenin signaling can induce chromosomal instability in colon cancer. Proc. Natl. Acad. Sci. U. S. A. 103, 10747\u201310752 (2006)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR126","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/path.1623","volume":"204","author":"W Giaretti","year":"2004","unstructured":"W. Giaretti et al., Chromosomal instability and APC gene mutations in human sporadic colorectal adenomas. J. Pathol. 204, 193\u2013199 (2004)","journal-title":"J. Pathol."},{"key":"16_CR127","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.cell.2015.05.033","volume":"161","author":"LE Dow","year":"2015","unstructured":"L.E. Dow et al., Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161, 1539\u20131552 (2015)","journal-title":"Cell"},{"key":"16_CR128","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ng.3127","volume":"46","author":"M Giannakis","year":"2014","unstructured":"M. Giannakis et al., RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 46, 1264\u20131266 (2014)","journal-title":"Nat. Genet."},{"key":"16_CR129","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature11282","volume":"488","author":"S Seshagiri","year":"2012","unstructured":"S. Seshagiri et al., Recurrent R-spondin fusions in colon cancer. Nature 488, 660\u2013664 (2012)","journal-title":"Nature"},{"key":"16_CR130","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Y. Wang et al., The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327, 1650\u20131653 (2010)","journal-title":"Science"},{"key":"16_CR131","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccr.2010.10.032","volume":"18","author":"J Yeung","year":"2010","unstructured":"J. Yeung et al., beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606\u2013618 (2010)","journal-title":"Cancer Cell"},{"key":"16_CR132","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1073\/pnas.0308648100","volume":"101","author":"D Lu","year":"2004","unstructured":"D. Lu et al., Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 101, 3118\u20133123 (2004)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR133","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood-2014-01-552067","volume":"124","author":"L Wang","year":"2014","unstructured":"L. Wang et al., Somatic mutation as a mechanism of Wnt\/beta-catenin pathway activation in CLL. Blood 124, 1089\u20131098 (2014)","journal-title":"Blood"},{"key":"16_CR134","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1073\/pnas.0911220107","volume":"107","author":"CC Liu","year":"2010","unstructured":"C.C. Liu, J. Prior, D. Piwnica-Worms, G. Bu, LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc. Natl. Acad. Sci. U. S. A. 107, 5136\u20135141 (2010)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR135","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4161\/cbt.3.1.561","volume":"3","author":"LR Howe","year":"2004","unstructured":"L.R. Howe, A.M. Brown, Wnt signaling and breast cancer. Cancer Biol. Ther. 3, 36\u201341 (2004)","journal-title":"Cancer Biol. Ther."},{"key":"16_CR136","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1073\/pnas.060025397","volume":"97","author":"SY Lin","year":"2000","unstructured":"S.Y. Lin et al., Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. U. S. A. 97, 4262\u20134266 (2000)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR137","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.2353\/ajpath.2010.091125","volume":"176","author":"AI Khramtsov","year":"2010","unstructured":"A.I. Khramtsov et al., Wnt\/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176, 2911\u20132920 (2010)","journal-title":"Am. J. Pathol."},{"key":"16_CR138","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/0092-8674(88)90220-6","volume":"55","author":"AS Tsukamoto","year":"1988","unstructured":"A.S. Tsukamoto, R. Grosschedl, R.C. Guzman, T. Parslow, H.E. Varmus, Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55, 619\u2013625 (1988)","journal-title":"Cell"},{"key":"16_CR139","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/jcp.22924","volume":"227","author":"M Klauzinska","year":"2012","unstructured":"M. Klauzinska et al., Rspo2\/Int7 regulates invasiveness and tumorigenic properties of mammary epithelial cells. J. Cell. Physiol. 227, 1960\u20131971 (2012)","journal-title":"J. Cell. Physiol."},{"key":"16_CR140","first-page":"27","volume":"2","author":"NN Yokoyama","year":"2014","unstructured":"N.N. Yokoyama, S. Shao, B.H. Hoang, D. Mercola, X. Zi, Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am. J. Clin. Exp. Urol. 2, 27\u201344 (2014)","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"16_CR141","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nrurol.2012.116","volume":"9","author":"RM Kypta","year":"2012","unstructured":"R.M. Kypta, J. Waxman, Wnt\/beta-catenin signalling in prostate cancer. Nat. Rev. Urol. 9, 418\u2013428 (2012)","journal-title":"Nat. Rev. Urol."},{"key":"16_CR142","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrurol.2017.144","volume":"14","author":"V Murillo-Garzon","year":"2017","unstructured":"V. Murillo-Garzon, R. Kypta, WNT signalling in prostate cancer. Nat. Rev. Urol. 14, 683\u2013696 (2017)","journal-title":"Nat. Rev. Urol."},{"key":"16_CR143","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/jcb.23070","volume":"112","author":"S Thiele","year":"2011","unstructured":"S. Thiele et al., Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J. Cell. Biochem. 112, 1593\u20131600 (2011)","journal-title":"J. Cell. Biochem."},{"key":"16_CR144","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.1158\/0008-5472.CAN-04-2704","volume":"64","author":"H Zhu","year":"2004","unstructured":"H. Zhu et al., Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res. 64, 7918\u20137926 (2004)","journal-title":"Cancer Res."},{"key":"16_CR145","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cncr.20518","volume":"101","author":"G Chen","year":"2004","unstructured":"G. Chen et al., Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101, 1345\u20131356 (2004)","journal-title":"Cancer"},{"key":"16_CR146","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1078-0432.CCR-11-2521","volume":"18","author":"X Wan","year":"2012","unstructured":"X. Wan et al., Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin. Cancer Res. 18, 726\u2013736 (2012)","journal-title":"Clin. Cancer Res."},{"key":"16_CR147","first-page":"1801","volume":"9","author":"A Taille de la","year":"2003","unstructured":"A. de la Taille et al., Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin. Cancer Res. 9, 1801\u20131807 (2003)","journal-title":"Clin. Cancer Res."},{"key":"16_CR148","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","volume":"78","author":"Z Zhang","year":"2018","unstructured":"Z. Zhang et al., Inhibition of the Wnt\/beta-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer. Cancer Res. 78, 3147\u20133162 (2018)","journal-title":"Cancer Res."},{"key":"16_CR149","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1158\/0008-5472.CAN-04-4407","volume":"65","author":"D Lodygin","year":"2005","unstructured":"D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold, H. Hermeking, Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 65, 4218\u20134227 (2005)","journal-title":"Cancer Res."},{"key":"16_CR150","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/pros.20607","volume":"67","author":"LG Horvath","year":"2007","unstructured":"L.G. Horvath et al., Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate 67, 1081\u20131090 (2007)","journal-title":"Prostate"},{"key":"16_CR151","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/1476-4598-9-162","volume":"9","author":"DS Yee","year":"2010","unstructured":"D.S. Yee et al., The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol. Cancer 9, 162 (2010)","journal-title":"Mol. Cancer"},{"key":"16_CR152","doi-asserted-by":"publisher","first-page":"9762","DOI":"10.1158\/0008-5472.CAN-05-0103","volume":"65","author":"X Zi","year":"2005","unstructured":"X. Zi et al., Expression of Frzb\/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 65, 9762\u20139770 (2005)","journal-title":"Cancer Res."},{"key":"16_CR153","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1038\/sj.onc.1206426","volume":"22","author":"B Bierie","year":"2003","unstructured":"B. Bierie et al., Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22, 3875\u20133887 (2003)","journal-title":"Oncogene"},{"key":"16_CR154","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/sj.onc.1205562","volume":"21","author":"F Gounari","year":"2002","unstructured":"F. Gounari et al., Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21, 4099\u20134107 (2002)","journal-title":"Oncogene"},{"key":"16_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003180","volume":"9","author":"JC Francis","year":"2013","unstructured":"J.C. Francis, M.K. Thomsen, M.M. Taketo, A. Swain, beta-Catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet. 9, e1003180 (2013)","journal-title":"PLoS Genet."},{"key":"16_CR156","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/onc.2010.560","volume":"30","author":"X Yu","year":"2011","unstructured":"X. Yu, Y. Wang, D.J. DeGraff, M.L. Wills, R.J. Matusik, Wnt\/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30, 1868\u20131879 (2011)","journal-title":"Oncogene"},{"key":"16_CR157","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","volume":"155","author":"FG Giancotti","year":"2013","unstructured":"F.G. Giancotti, Mechanisms governing metastatic dormancy and reactivation. Cell 155, 750\u2013764 (2013)","journal-title":"Cell"},{"key":"16_CR158","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2016.44","volume":"16","author":"PI Croucher","year":"2016","unstructured":"P.I. Croucher, M.M. McDonald, T.J. Martin, Bone metastasis: the importance of the neighbourhood. Nat. Rev. Cancer 16, 373\u2013386 (2016)","journal-title":"Nat. Rev. Cancer"},{"key":"16_CR159","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/sj.onc.1210694","volume":"27","author":"ZG Li","year":"2008","unstructured":"Z.G. Li et al., Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27, 596\u2013603 (2008)","journal-title":"Oncogene"},{"key":"16_CR160","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W","volume":"45","author":"DR Chesire","year":"2000","unstructured":"D.R. Chesire, C.M. Ewing, J. Sauvageot, G.S. Bova, W.B. Isaacs, Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 45, 323\u2013334 (2000)","journal-title":"Prostate"},{"key":"16_CR161","first-page":"2520","volume":"58","author":"HJ Voeller","year":"1998","unstructured":"H.J. Voeller, C.I. Truica, E.P. Gelmann, Beta-catenin mutations in human prostate cancer. Cancer Res. 58, 2520\u20132523 (1998)","journal-title":"Cancer Res."},{"key":"16_CR162","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","volume":"66","author":"P Rajan","year":"2014","unstructured":"P. Rajan et al., Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur. Urol. 66, 32\u201339 (2014)","journal-title":"Eur. Urol."},{"issue":"5","key":"16_CR163","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2019.03.020","volume":"76","author":"William S. Chen","year":"2019","unstructured":"W.S. Chen et al., Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Eur. Urol. (2019). https:\/\/doi.org\/10.1016\/j.eururo.2019.03.020","journal-title":"European Urology"},{"key":"16_CR164","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/annonc\/mdx689","volume":"29","author":"L Wang","year":"2018","unstructured":"L. Wang et al., A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann. Oncol. 29, 352\u2013360 (2018)","journal-title":"Ann. Oncol."},{"key":"16_CR165","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","volume":"75","author":"M Cojoc","year":"2015","unstructured":"M. Cojoc et al., Aldehyde dehydrogenase is regulated by beta-catenin\/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res. 75, 1482\u20131494 (2015)","journal-title":"Cancer Res."},{"key":"16_CR166","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12931-017-0537-6","volume":"18","author":"M Vesel","year":"2017","unstructured":"M. Vesel et al., ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respir. Res. 18, 52 (2017)","journal-title":"Respir. Res."},{"key":"16_CR167","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/pros.20581","volume":"67","author":"M Takeda","year":"2007","unstructured":"M. Takeda et al., The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67, 955\u2013967 (2007)","journal-title":"Prostate"},{"key":"16_CR168","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1535-7163.MCT-17-0179","volume":"16","author":"AP Lombard","year":"2017","unstructured":"A.P. Lombard et al., ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol. Cancer Ther. 16, 2257\u20132266 (2017)","journal-title":"Mol. Cancer Ther."},{"key":"16_CR169","first-page":"4709","volume":"60","author":"CI Truica","year":"2000","unstructured":"C.I. Truica, S. Byers, E.P. Gelmann, Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60, 4709\u20134713 (2000)","journal-title":"Cancer Res."},{"key":"16_CR170","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2121-9-4","volume":"9","author":"L Schweizer","year":"2008","unstructured":"L. Schweizer et al., The androgen receptor can signal through Wnt\/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 9, 4 (2008)","journal-title":"BMC Cell Biol."},{"key":"16_CR171","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1158\/0008-5472.CAN-08-3380","volume":"69","author":"Y Li","year":"2009","unstructured":"Y. Li et al., LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 69, 3332\u20133338 (2009)","journal-title":"Cancer Res."},{"key":"16_CR172","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1196\/annals.1336.009","volume":"1061","author":"X Yu","year":"2005","unstructured":"X. Yu et al., Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann. N. Y. Acad. Sci. 1061, 77\u201393 (2005)","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"16_CR173","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/modpathol.2017.44","volume":"30","author":"JW Park","year":"2017","unstructured":"J.W. Park, J.K. Lee, O.N. Witte, J. Huang, FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod. Pathol. 30(9), 1262\u20131272 (2017)","journal-title":"Mod. Pathol."},{"key":"16_CR174","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuron.2005.02.023","volume":"46","author":"TJ Raay Van","year":"2005","unstructured":"T.J. Van Raay et al., Frizzled 5 signaling governs the neural potential of progenitors in the developing Xenopus retina. Neuron 46, 23\u201336 (2005)","journal-title":"Neuron"},{"key":"16_CR175","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0002-9440(10)65297-2","volume":"154","author":"VJ Wielenga","year":"1999","unstructured":"V.J. Wielenga et al., Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 154, 515\u2013523 (1999)","journal-title":"Am. J. Pathol."},{"key":"16_CR176","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.humpath.2008.07.014","volume":"40","author":"RA Simon","year":"2009","unstructured":"R.A. Simon et al., CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum. Pathol. 40, 252\u2013258 (2009)","journal-title":"Hum. Pathol."},{"key":"16_CR177","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/pros.20928","volume":"69","author":"GS Palapattu","year":"2009","unstructured":"G.S. Palapattu et al., Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 69, 787\u2013798 (2009)","journal-title":"Prostate"},{"key":"16_CR178","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1242\/dev.023176","volume":"135","author":"D Berge ten","year":"2008","unstructured":"D. ten Berge, S.A. Brugmann, J.A. Helms, R. Nusse, Wnt and FGF signals interact to coordinate growth with cell fate specification during limb development. Development 135, 3247\u20133257 (2008)","journal-title":"Development"},{"key":"16_CR179","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/ijc.26402","volume":"131","author":"M Ciarlo","year":"2012","unstructured":"M. Ciarlo et al., Regulation of neuroendocrine differentiation by AKT\/hnRNPK\/AR\/beta-catenin signaling in prostate cancer cells. Int. J. Cancer 131, 582\u2013590 (2012)","journal-title":"Int. J. Cancer"},{"key":"16_CR180","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420\u20131428 (2009)","journal-title":"J. Clin. Invest."},{"key":"16_CR181","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc2620","volume":"9","author":"K Polyak","year":"2009","unstructured":"K. Polyak, R.A. Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265\u2013273 (2009)","journal-title":"Nat. Rev. Cancer"},{"key":"16_CR182","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1432-0436.2006.00075.x","volume":"74","author":"EJ Robson","year":"2006","unstructured":"E.J. Robson, W.T. Khaled, K. Abell, C.J. Watson, Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation 74, 254\u2013264 (2006)","journal-title":"Differentiation"},{"key":"16_CR183","doi-asserted-by":"publisher","first-page":"13820","DOI":"10.1073\/pnas.0905718106","volume":"106","author":"CJ Creighton","year":"2009","unstructured":"C.J. Creighton et al., Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U. S. A. 106, 13820\u201313825 (2009)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR184","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"K.R. Fischer et al., Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472\u2013476 (2015)","journal-title":"Nature"},{"key":"16_CR185","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"X. Zheng et al., Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525\u2013530 (2015)","journal-title":"Nature"},{"key":"16_CR186","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"S.A. Mani et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704\u2013715 (2008)","journal-title":"Cell"},{"key":"16_CR187","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/stem.467","volume":"28","author":"VL Battula","year":"2010","unstructured":"V.L. Battula et al., Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435\u20131445 (2010)","journal-title":"Stem Cells"},{"key":"16_CR188","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a002915","volume":"2","author":"J Heuberger","year":"2010","unstructured":"J. Heuberger, W. Birchmeier, Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb. Perspect. Biol. 2, a002915 (2010)","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"16_CR189","doi-asserted-by":"publisher","first-page":"16654","DOI":"10.1073\/pnas.1205822109","volume":"109","author":"ZQ Wu","year":"2012","unstructured":"Z.Q. Wu et al., Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc. Natl. Acad. Sci. U. S. A. 109, 16654\u201316659 (2012)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR190","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1083\/jcb.200308162","volume":"163","author":"M Conacci-Sorrell","year":"2003","unstructured":"M. Conacci-Sorrell et al., Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J. Cell Biol. 163, 847\u2013857 (2003)","journal-title":"J. Cell Biol."},{"key":"16_CR191","first-page":"1906","volume":"63","author":"LR Howe","year":"2003","unstructured":"L.R. Howe, O. Watanabe, J. Leonard, A.M. Brown, Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 63, 1906\u20131913 (2003)","journal-title":"Cancer Res."},{"key":"16_CR192","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature01458","volume":"422","author":"C Jamora","year":"2003","unstructured":"C. Jamora, R. DasGupta, P. Kocieniewski, E. Fuchs, Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 422, 317\u2013322 (2003)","journal-title":"Nature"},{"key":"16_CR193","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1038\/sj.onc.1202627","volume":"18","author":"HC Crawford","year":"1999","unstructured":"H.C. Crawford et al., The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18, 2883\u20132891 (1999)","journal-title":"Oncogene"},{"key":"16_CR194","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1006\/cbir.2002.0901","volume":"26","author":"K Kim","year":"2002","unstructured":"K. Kim, Z. Lu, E.D. Hay, Direct evidence for a role of beta-catenin\/LEF-1 signaling pathway in induction of EMT. Cell Biol. Int. 26, 463\u2013476 (2002)","journal-title":"Cell Biol. Int."},{"key":"16_CR195","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/labinvest.2015.144","volume":"96","author":"K Yang","year":"2016","unstructured":"K. Yang et al., The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab. Investig. 96, 116\u2013136 (2016)","journal-title":"Lab. Investig."},{"key":"16_CR196","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007971","volume":"4","author":"BJ Merrill","year":"2012","unstructured":"B.J. Merrill, Wnt pathway regulation of embryonic stem cell self-renewal. Cold Spring Harb. Perspect. Biol. 4, a007971 (2012)","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"16_CR197","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ceb.2013.01.004","volume":"25","author":"JD Holland","year":"2013","unstructured":"J.D. Holland, A. Klaus, A.N. Garratt, W. Birchmeier, Wnt signaling in stem and cancer stem cells. Curr. Opin. Cell Biol. 25, 254\u2013264 (2013)","journal-title":"Curr. Opin. Cell Biol."},{"key":"16_CR198","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nature06835","volume":"452","author":"I Malanchi","year":"2008","unstructured":"I. Malanchi et al., Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452, 650\u2013653 (2008)","journal-title":"Nature"},{"key":"16_CR199","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nm979","volume":"10","author":"N Sato","year":"2004","unstructured":"N. Sato, L. Meijer, L. Skaltsounis, P. Greengard, A.H. Brivanlou, Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55\u201363 (2004)","journal-title":"Nat. Med."},{"key":"16_CR200","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.stem.2008.08.017","volume":"3","author":"F Lluis","year":"2008","unstructured":"F. Lluis, E. Pedone, S. Pepe, M.P. Cosma, Periodic activation of Wnt\/beta-catenin signaling enhances somatic cell reprogramming mediated by cell fusion. Cell Stem Cell 3, 493\u2013507 (2008)","journal-title":"Cell Stem Cell"},{"key":"16_CR201","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1126\/science.1218370","volume":"336","author":"K Hoffmeyer","year":"2012","unstructured":"K. Hoffmeyer et al., Wnt\/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336, 1549\u20131554 (2012)","journal-title":"Science"},{"key":"16_CR202","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/onc.2012.611","volume":"33","author":"J Zeilstra","year":"2014","unstructured":"J. Zeilstra et al., Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene 33, 665\u2013670 (2014)","journal-title":"Oncogene"},{"key":"16_CR203","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","volume":"51","author":"M Katoh","year":"2017","unstructured":"M. Katoh, Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int. J. Oncol. 51, 1357\u20131369 (2017)","journal-title":"Int. J. Oncol."},{"key":"16_CR204","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.stemcr.2015.04.003","volume":"4","author":"BE Wang","year":"2015","unstructured":"B.E. Wang et al., Castration-resistant Lgr5(+) cells are long-lived stem cells required for prostatic regeneration. Stem Cell Rep. 4, 768\u2013779 (2015)","journal-title":"Stem Cell Rep."},{"key":"16_CR205","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/pros.20770","volume":"68","author":"CS Ontiveros","year":"2008","unstructured":"C.S. Ontiveros, S.N. Salm, E.L. Wilson, Axin2 expression identifies progenitor cells in the murine prostate. Prostate 68, 1263\u20131272 (2008)","journal-title":"Prostate"},{"key":"16_CR206","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/1078-0432.CCR-15-0190","volume":"22","author":"EJ Yun","year":"2016","unstructured":"E.J. Yun et al., Targeting cancer stem cells in castration-resistant prostate cancer. Clin. Cancer Res. 22, 670\u2013679 (2016)","journal-title":"Clin. Cancer Res."},{"key":"16_CR207","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature01593","volume":"423","author":"T Reya","year":"2003","unstructured":"T. Reya et al., A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409\u2013414 (2003)","journal-title":"Nature"},{"key":"16_CR208","first-page":"2701","volume":"28","author":"N Kawaguchi-Ihara","year":"2008","unstructured":"N. Kawaguchi-Ihara, I. Murohashi, N. Nara, S. Tohda, Promotion of the self-renewal capacity of human acute leukemia cells by Wnt3A. Anticancer Res. 28, 2701\u20132704 (2008)","journal-title":"Anticancer Res."},{"key":"16_CR209","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/cr.2009.43","volume":"19","author":"I Bisson","year":"2009","unstructured":"I. Bisson, D.M. Prowse, WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 19, 683\u2013697 (2009)","journal-title":"Cell Res."},{"key":"16_CR210","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1158\/0008-5472.CAN-16-1887","volume":"77","author":"K Zhang","year":"2017","unstructured":"K. Zhang et al., WNT\/beta-catenin directs self-renewal symmetric cell division of hTERT(high) prostate cancer stem cells. Cancer Res. 77, 2534\u20132547 (2017)","journal-title":"Cancer Res."},{"key":"16_CR211","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1016\/j.celrep.2018.08.062","volume":"24","author":"BA Smith","year":"2018","unstructured":"B.A. Smith et al., A human adult stem cell signature marks aggressive variants across epithelial cancers. Cell Rep. 24, 3353\u20133366.e5 (2018)","journal-title":"Cell Rep."},{"key":"16_CR212","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/pros.20895","volume":"69","author":"P Sotomayor","year":"2009","unstructured":"P. Sotomayor, A. Godoy, G.J. Smith, W.J. Huss, Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 69, 401\u2013410 (2009)","journal-title":"Prostate"},{"key":"16_CR213","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/pros.20934","volume":"69","author":"N Monsef","year":"2009","unstructured":"N. Monsef, M. Soller, M. Isaksson, P.A. Abrahamsson, I. Panagopoulos, The expression of pluripotency marker Oct 3\/4 in prostate cancer and benign prostate hyperplasia. Prostate 69, 909\u2013916 (2009)","journal-title":"Prostate"},{"key":"16_CR214","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2174\/0929867321666131129125953","volume":"21","author":"A Cueto","year":"2014","unstructured":"A. Cueto, F. Burigana, A. Nicolini, F. Lugnani, Neuroendocrine tumors of the lung: hystological classification, diagnosis, traditional and new therapeutic approaches. Curr. Med. Chem. 21, 1107\u20131116 (2014)","journal-title":"Curr. Med. Chem."},{"key":"16_CR215","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"M. Milanovic et al., Senescence-associated reprogramming promotes cancer stemness. Nature 553, 96\u2013100 (2018)","journal-title":"Nature"},{"key":"16_CR216","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"D. Robinson et al., Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015)","journal-title":"Cell"},{"key":"16_CR217","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"J. Armenia et al., The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645\u2013651 (2018)","journal-title":"Nat. Genet."},{"key":"16_CR218","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","volume":"2","author":"AW Wyatt","year":"2016","unstructured":"A.W. Wyatt et al., Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2, 1598\u20131606 (2016)","journal-title":"JAMA Oncol."},{"key":"16_CR219","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/path.1449","volume":"201","author":"C Wissmann","year":"2003","unstructured":"C. Wissmann et al., WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J. Pathol. 201, 204\u2013212 (2003)","journal-title":"J. Pathol."},{"key":"16_CR220","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/ijc.27798","volume":"132","author":"AS Perry","year":"2013","unstructured":"A.S. Perry et al., Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int. J. Cancer 132, 1771\u20131780 (2013)","journal-title":"Int. J. Cancer"},{"key":"16_CR221","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1158\/1078-0432.CCR-0707-03","volume":"10","author":"LG Horvath","year":"2004","unstructured":"L.G. Horvath et al., Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin. Cancer Res. 10, 615\u2013625 (2004)","journal-title":"Clin. Cancer Res."},{"key":"16_CR222","doi-asserted-by":"publisher","first-page":"10423","DOI":"10.1158\/0008-5472.CAN-05-0824","volume":"65","author":"MS Joesting","year":"2005","unstructured":"M.S. Joesting et al., Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 65, 10423\u201310430 (2005)","journal-title":"Cancer Res."},{"key":"16_CR223","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/j.1365-2559.2011.04073.x","volume":"59","author":"G O\u2019Hurley","year":"2011","unstructured":"G. O\u2019Hurley et al., The role of secreted frizzled-related protein 2 expression in prostate cancer. Histopathology 59, 1240\u20131248 (2011)","journal-title":"Histopathology"},{"key":"16_CR224","doi-asserted-by":"publisher","first-page":"E3395","DOI":"10.1073\/pnas.1217982109","volume":"109","author":"Y Zong","year":"2012","unstructured":"Y. Zong et al., Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 109, E3395\u2013E3404 (2012)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR225","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/1078-0432.CCR-13-1184","volume":"20","author":"O Dakhova","year":"2014","unstructured":"O. Dakhova, D. Rowley, M. Ittmann, Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin. Cancer Res. 20, 100\u2013109 (2014)","journal-title":"Clin. Cancer Res."},{"key":"16_CR226","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.cellsig.2006.02.014","volume":"18","author":"N Carayol","year":"2006","unstructured":"N. Carayol, C.Y. Wang, IKKalpha stabilizes cytosolic beta-catenin by inhibiting both canonical and non-canonical degradation pathways. Cell. Signal. 18, 1941\u20131946 (2006)","journal-title":"Cell. Signal."},{"key":"16_CR227","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cell.2006.08.036","volume":"127","author":"L Yang","year":"2006","unstructured":"L. Yang, C. Lin, Z.R. Liu, P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127, 139\u2013155 (2006)","journal-title":"Cell"},{"key":"16_CR228","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-07-6289","volume":"68","author":"VR Placencio","year":"2008","unstructured":"V.R. Placencio et al., Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res. 68, 4709\u20134718 (2008)","journal-title":"Cancer Res."},{"key":"16_CR229","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002186","volume":"3","author":"BE Wang","year":"2008","unstructured":"B.E. Wang, X.D. Wang, J.A. Ernst, P. Polakis, W.Q. Gao, Regulation of epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt signaling. PLoS One 3, e2186 (2008)","journal-title":"PLoS One"},{"key":"16_CR230","doi-asserted-by":"publisher","first-page":"26259","DOI":"10.18632\/oncotarget.8456","volume":"7","author":"S Kregel","year":"2016","unstructured":"S. Kregel et al., Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 7, 26259\u201326274 (2016)","journal-title":"Oncotarget"},{"key":"16_CR231","doi-asserted-by":"publisher","first-page":"9918","DOI":"10.1158\/0008-5472.CAN-08-1718","volume":"68","author":"G Wang","year":"2008","unstructured":"G. Wang, J. Wang, M.D. Sadar, Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res. 68, 9918\u20139927 (2008)","journal-title":"Cancer Res."},{"key":"16_CR232","doi-asserted-by":"publisher","first-page":"15710","DOI":"10.1073\/pnas.1218168110","volume":"110","author":"E Lee","year":"2013","unstructured":"E. Lee et al., Inhibition of androgen receptor and beta-catenin activity in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 110, 15710\u201315715 (2013)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR233","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mce.2017.02.008","volume":"462","author":"JA Schneider","year":"2018","unstructured":"J.A. Schneider, S.K. Logan, Revisiting the role of Wnt\/beta-catenin signaling in prostate cancer. Mol. Cell. Endocrinol. 462, 3\u20138 (2018)","journal-title":"Mol. Cell. Endocrinol."},{"key":"16_CR234","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/pros.22828","volume":"74","author":"L Antony","year":"2014","unstructured":"L. Antony, F. van der Schoor, S.L. Dalrymple, J.T. Isaacs, Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR\/beta-catenin\/TCF-4 complex inhibition of c-MYC transcription. Prostate 74, 1118\u20131131 (2014)","journal-title":"Prostate"},{"key":"16_CR235","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1038\/sj.onc.1206802","volume":"22","author":"DJ Mulholland","year":"2003","unstructured":"D.J. Mulholland, J.T. Read, P.S. Rennie, M.E. Cox, C.C. Nelson, Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22, 5602\u20135613 (2003)","journal-title":"Oncogene"},{"key":"16_CR236","doi-asserted-by":"publisher","first-page":"8453","DOI":"10.1038\/sj.onc.1206049","volume":"21","author":"DR Chesire","year":"2002","unstructured":"D.R. Chesire, W.B. Isaacs, Ligand-dependent inhibition of beta-catenin\/TCF signaling by androgen receptor. Oncogene 21, 8453\u20138469 (2002)","journal-title":"Oncogene"},{"key":"16_CR237","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1432-0436.2006.00135.x","volume":"75","author":"XD Wang","year":"2007","unstructured":"X.D. Wang et al., Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation 75, 219\u2013234 (2007)","journal-title":"Differentiation"},{"key":"16_CR238","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1038\/sj.onc.1205352","volume":"21","author":"DR Chesire","year":"2002","unstructured":"D.R. Chesire, C.M. Ewing, W.R. Gage, W.B. Isaacs, In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21, 2679\u20132694 (2002)","journal-title":"Oncogene"},{"key":"16_CR239","doi-asserted-by":"publisher","first-page":"42276","DOI":"10.1074\/jbc.M104227200","volume":"276","author":"C Lamberti","year":"2001","unstructured":"C. Lamberti et al., Regulation of beta-catenin function by the IkappaB kinases. J. Biol. Chem. 276, 42276\u201342286 (2001)","journal-title":"J. Biol. Chem."},{"key":"16_CR240","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1172\/JCI78815","volume":"126","author":"F Ma","year":"2016","unstructured":"F. Ma et al., SOX9 drives WNT pathway activation in prostate cancer. J. Clin. Invest. 126, 1745\u20131758 (2016)","journal-title":"J. Clin. Invest."},{"key":"16_CR241","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cell.2008.01.052","volume":"133","author":"X Wu","year":"2008","unstructured":"X. Wu et al., Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell 133, 340\u2013353 (2008)","journal-title":"Cell"},{"key":"16_CR242","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1083\/jcb.153.6.1161","volume":"153","author":"S Persad","year":"2001","unstructured":"S. Persad, A.A. Troussard, T.R. McPhee, D.J. Mulholland, S. Dedhar, Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell\/lymphoid enhancer factor 1-mediated transcriptional activation. J. Cell Biol. 153, 1161\u20131174 (2001)","journal-title":"J. Cell Biol."},{"key":"16_CR243","doi-asserted-by":"publisher","first-page":"G856","DOI":"10.1152\/ajpgi.00178.2011","volume":"301","author":"DS Byun","year":"2011","unstructured":"D.S. Byun et al., Intestinal epithelial-specific PTEN inactivation results in tumor formation. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G856\u2013G864 (2011)","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"16_CR244","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/path.4977","volume":"243","author":"MT Jefferies","year":"2017","unstructured":"M.T. Jefferies et al., PTEN loss and activation of K-RAS and beta-catenin cooperate to accelerate prostate tumourigenesis. J. Pathol. 243, 442\u2013456 (2017)","journal-title":"J. Pathol."},{"key":"16_CR245","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"FX Yu","year":"2015","unstructured":"F.X. Yu, B. Zhao, K.L. Guan, Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811\u2013828 (2015)","journal-title":"Cell"},{"key":"16_CR246","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/1541-7786.MCR-15-0305","volume":"14","author":"U Ehmer","year":"2016","unstructured":"U. Ehmer, J. Sage, Control of proliferation and cancer growth by the Hippo signaling pathway. Mol. Cancer Res. 14, 127\u2013140 (2016)","journal-title":"Mol. Cancer Res."},{"key":"16_CR247","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/cas.13013","volume":"107","author":"T Ito","year":"2016","unstructured":"T. Ito et al., Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci. 107, 1527\u20131538 (2016)","journal-title":"Cancer Sci."},{"key":"16_CR248","doi-asserted-by":"publisher","first-page":"8126","DOI":"10.1038\/ncomms9126","volume":"6","author":"G Kuser-Abali","year":"2015","unstructured":"G. Kuser-Abali, A. Alptekin, M. Lewis, I.P. Garraway, B. Cinar, YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat. Commun. 6, 8126 (2015)","journal-title":"Nat. Commun."},{"key":"16_CR249","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1128\/MCB.00102-15","volume":"35","author":"L Zhang","year":"2015","unstructured":"L. Zhang et al., The Hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol. Cell. Biol. 35, 1350\u20131362 (2015)","journal-title":"Mol. Cell. Biol."},{"key":"16_CR250","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cell.2012.11.027","volume":"151","author":"L Azzolin","year":"2012","unstructured":"L. Azzolin et al., Role of TAZ as mediator of Wnt signaling. Cell 151, 1443\u20131456 (2012)","journal-title":"Cell"},{"key":"16_CR251","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1126\/science.1199010","volume":"332","author":"T Heallen","year":"2011","unstructured":"T. Heallen et al., Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458\u2013461 (2011)","journal-title":"Science"},{"key":"16_CR252","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.cell.2012.11.026","volume":"151","author":"J Rosenbluh","year":"2012","unstructured":"J. Rosenbluh et al., beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457\u20131473 (2012)","journal-title":"Cell"},{"key":"16_CR253","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","volume":"158","author":"L Azzolin","year":"2014","unstructured":"L. Azzolin et al., YAP\/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158, 157\u2013170 (2014)","journal-title":"Cell"},{"key":"16_CR254","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.devcel.2010.03.007","volume":"18","author":"X Varelas","year":"2010","unstructured":"X. Varelas et al., The Hippo pathway regulates Wnt\/beta-catenin signaling. Dev. Cell 18, 579\u2013591 (2010)","journal-title":"Dev. Cell"},{"key":"16_CR255","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1074\/jbc.RA118.002715","volume":"293","author":"SW Plouffe","year":"2018","unstructured":"S.W. Plouffe et al., The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J. Biol. Chem. 293, 11230\u201311240 (2018)","journal-title":"J. Biol. Chem."},{"key":"16_CR256","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature11693","volume":"493","author":"ER Barry","year":"2013","unstructured":"E.R. Barry et al., Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106\u2013110 (2013)","journal-title":"Nature"},{"key":"16_CR257","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","volume":"12","author":"N Takebe","year":"2015","unstructured":"N. Takebe et al., Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445\u2013464 (2015)","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"16_CR258","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"R. Nusse, H. Clevers, Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985\u2013999 (2017)","journal-title":"Cell"},{"key":"16_CR259","doi-asserted-by":"publisher","first-page":"12682","DOI":"10.1073\/pnas.0404875101","volume":"101","author":"KH Emami","year":"2004","unstructured":"K.H. Emami et al., A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. U. S. A. 101, 12682\u201312687 (2004)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR260","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/cas.12471","volume":"105","author":"HJ Lenz","year":"2014","unstructured":"H.J. Lenz, M. Kahn, Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci. 105, 1087\u20131092 (2014)","journal-title":"Cancer Sci."},{"key":"16_CR261","doi-asserted-by":"publisher","first-page":"10267","DOI":"10.1021\/bi9009677","volume":"48","author":"M Chen","year":"2009","unstructured":"M. Chen et al., The anti-helminthic niclosamide inhibits Wnt\/Frizzled1 signaling. Biochemistry 48, 10267\u201310274 (2009)","journal-title":"Biochemistry"},{"key":"16_CR262","doi-asserted-by":"publisher","first-page":"15495","DOI":"10.1021\/bi0512602","volume":"44","author":"J Shan","year":"2005","unstructured":"J. Shan, D.L. Shi, J. Wang, J. Zheng, Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44, 15495\u201315503 (2005)","journal-title":"Biochemistry"},{"key":"16_CR263","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bbrc.2004.12.151","volume":"328","author":"CH Park","year":"2005","unstructured":"C.H. Park et al., Quercetin, a potent inhibitor against beta-catenin\/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun. 328, 227\u2013234 (2005)","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"16_CR264","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/leu.2014.340","volume":"29","author":"W Fiskus","year":"2015","unstructured":"W. Fiskus et al., Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia 29, 1267\u20131278 (2015)","journal-title":"Leukemia"},{"key":"16_CR265","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1073\/pnas.0610299104","volume":"104","author":"K Sukhdeo","year":"2007","unstructured":"K. Sukhdeo et al., Targeting the beta-catenin\/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl. Acad. Sci. U. S. A. 104, 7516\u20137521 (2007)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR266","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nchembio.137","volume":"5","author":"B Chen","year":"2009","unstructured":"B. Chen et al., Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5, 100\u2013107 (2009)","journal-title":"Nat. Chem. Biol."},{"key":"16_CR267","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1021\/acs.jmedchem.8b00095","volume":"61","author":"B Garcia-Reyes","year":"2018","unstructured":"B. Garcia-Reyes et al., Discovery of inhibitor of Wnt production 2 (IWP-2) and related compounds as selective ATP-competitive inhibitors of casein kinase 1 (CK1) delta\/epsilon. J. Med. Chem. 61, 4087\u20134102 (2018)","journal-title":"J. Med. Chem."},{"key":"16_CR268","doi-asserted-by":"publisher","first-page":"20224","DOI":"10.1073\/pnas.1314239110","volume":"110","author":"J Liu","year":"2013","unstructured":"J. Liu et al., Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. U. S. A. 110, 20224\u201320229 (2013)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16_CR269","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/0008-5472.CAN-12-2258","volume":"73","author":"KD Proffitt","year":"2013","unstructured":"K.D. Proffitt et al., Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 73, 502\u2013507 (2013)","journal-title":"Cancer Res."},{"key":"16_CR270","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nature08356","volume":"461","author":"SM Huang","year":"2009","unstructured":"S.M. Huang et al., Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614\u2013620 (2009)","journal-title":"Nature"}],"container-title":["Advances in Experimental Medicine and Biology","Prostate Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-32656-2_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T20:32:15Z","timestamp":1613334735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-32656-2_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030326555","9783030326562"],"references-count":270,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-32656-2_16","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"4 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}